Blog

Prostate cancer ‘Rosetta stone’ paves way to new therapies

— almost 90% of metastatic prostate cancers have treatable defects —

A cancer genome sequencing study published last week in the prestigious journal Cell provides new and surprising information about metastatic prostate cancer that has become castration-resistant.

An international consortium of scientists pieced together the first comprehensive map of genetic mutations linked to metastatic prostate cancer from 150 patients and found that almost 90% of the men whose DNA they studied carried potentially treatable defects.

The findings suggest that these advanced cancers may be treated using a precision medicine approach, using a range of medicines that target specific gene mutations. Many of these medicines are already in use or undergoing clinical trials. They also learned that 8% of the men were born with genetic faults that predisposed them to prostate cancer, strengthening the case for screening people with a family history of the disease.

This research is groundbreaking because it provides solid evidence that there may be effective new treatment options for those with advanced prostate cancer who have become resistant to current therapies.

Click to read the original article abstract (you’ll need a subscription to read the entire manuscript).

Local coverage:

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Recent Posts

15th Annual Personalized Medicine Conference Posted on Nov 9 19 at 5:14pm
Evaluating the measurement properties of EPIC-26 Posted on Nov 6 19 at 12:19pm
APCaRI 2019 Fall Symposium Posted on Oct 22 19 at 12:28pm

Its nearly time for the 2018 APCaRI Fall Symposium!

APCaRI will celebrate its 11th research meeting at the Banff Park Lodge, in Banff, Alberta on October 26 to 27, 2018. Please welcome our two invited speakers who will be joining the Symposium this year:

Alison Allan, PhD
Chair, Department of Anatomy & Cell Biology
Associate Professor, Departments of Anatomy & Cell Biology and Oncology
Western University, Ontario CA
and
Melina Cimler, PhD
CEO and Founder
PandiaDx LLC
Frisco, Texas

Previous fall symposia have had over 60 participants participating in this fun and enriching event, including clinicians, scientists, clinical research personnel, trainees, benefactors and representatives of PCa support groups.
Rose Pink Photography was at the 2017 APCaRI Fall Symposium and took these excellent images of the meeting, including the group photo seen in the featured image!

Plan on attending the 2018 Fall symposium to discuss and share ideas and enjoy the beautiful Rockies!
The APCaRI Fall symposium is generously supported by the Alberta Cancer Foundation and its’ donors.

- Perrin Beatty